Endometrial cancer recurrent

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
6 Unique sponsors
10 Unique IMPs
5 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
— ATC code not specified 2
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Anthracycline 1 substance
Taxane 1 substance
Antibody-drug conjugate (ADC) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 4 Phase I/II: 1 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

4 trials
  • BioNTech SE Commercial
    DB-1303; DOXORUBICIN HYDROCHLORIDE; PACLITAXEL
    2023-507525-42-00 15 countries 2025 n=222
    Recruiting
  • Genmab A/S Commercial
    RINATABART SESUTECAN
    2024-519818-31-01 11 countries n=226
    Pending
  • Gilead Sciences Inc. Commercial
    DOXORUBICIN HYDROCHLORIDE; SACITUZUMAB GOVITECAN
    2024-511957-23-00 7 countries 2025 n=179
    Ended
  • Karyopharm Therapeutics Inc. Commercial
    IMP not specified
    2024-513167-68-00 6 countries 2017 n=70
    Ended

Phase I/II

1 trial
  • Vall D Hebron Institute Of Oncology Academic
    DOSTARLIMAB; LURBINECTEDIN
    2023-508583-30-00 1 country n=58
    Ended

Phase I (First in Human)

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BRIMONIDINE TARTRATE; IMGN151; PREDNISOLONE ACETATE
    2023-506842-22-00 7 countries 2025 n=176
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BioNTech SE Commercial 1 Phase III 1
Genmab A/S Commercial 1 Phase III 0
Gilead Sciences Inc. Commercial 1 Phase III 0
Karyopharm Therapeutics Inc. Commercial 1 Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (First in Human) 0
Vall D Hebron Institute Of Oncology Academic 1 Phase I/II 0
New trials by year
2025
3
← All indication landscapes